Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Pre-Mkt 09-21 05:59:29 EDT

4.80

+0.03

+0.63%

盘前4.89

+0.09+1.87%

05:00 EDT

High4.85	Low4.76	Vol1.11M
Open4.80	D1 Closing4.77	Amplitude1.89%
Mkt Cap133.71M	Tradable Cap130.68M	Total Shares27.86M
T/O5.32M	T/O Rate4.07%	Tradable Shares27.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":4.8,"timestamp":1789761600000,"preClose":4.77,"halted":0,"volume":1109036,"hourTrading":{"tag":"盘前","latestPrice":4.89,"preClose":4.8,"latestTime":"05:00 EDT","volume":100,"amount":488.99999999999994,"timestamp":1789981259868,"change":0.09,"changeRate":0.01875,"amplitude":0},"delay":0,"changeRate":0.006289308176100681,"floatShares":27225798,"shares":27855300,"eps":-1.558501,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"09-21 05:59:29 EDT","open":4.8,"high":4.85,"low":4.76,"amount":5324718.8369932,"amplitude":0.018868,"askPrice":5.25,"askSize":14500,"bidPrice":4.75,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-1.558501,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789997400000},"marketStatusCode":1,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":4.8,"preHourTrading":{"tag":"盘前","latestPrice":4.89,"preClose":4.8,"latestTime":"05:00 EDT","volume":100,"amount":488.99999999999994,"timestamp":1789981259868,"change":0.09,"changeRate":0.01875,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.82,"preClose":4.8,"latestTime":"19:30 EDT","volume":104892,"amount":503521.0709,"timestamp":1789774205401,"change":0.02,"changeRate":0.004167,"amplitude":0.006083},"volumeRatio":1.1016700138104436,"impliedVol":0.765,"impliedVolPercentile":0.2431},"requestUrl":"/m/hq/s/UNCY","defaultTab":"news","newsList":[{"id":"2667866173","title":"Unicycive Therapeutics Faces Securities Lawsuit After 39% Stock Plunge Over Repeat FDA Manufacturing Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2667866173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667866173?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:44","pubTimestamp":1789393468,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics, Inc. ($UNCY) is facing a federal securities lawsuit after its shares fell sharply following news that the FDA had issued a ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/unicycive-therapeutics-faces-securities-lawsuit-after-39-stock-plunge-over-repeat-fda-manufacturing-setback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/unicycive-therapeutics-faces-securities-lawsuit-after-39-stock-plunge-over-repeat-fda-manufacturing-setback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LABU","UNCY","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666537805","title":"Unicycive Therapeutics Outlines Oxylanthanum Carbonate Program for Hyperphosphatemia in Dialysis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666537805","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666537805?lang=en_us&edition=fundamental","pubTime":"2026-09-10 03:03","pubTimestamp":1788980586,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics outlines oxylanthanum carbonate program for hyperphosphatemia in dialysis patientsUnicycive outlined near-term plans to resubmit the NDA for oxylanthanum carbonate, its lead pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL55XxTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855885","title":"Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855885","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855885?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:05","pubTimestamp":1788260700,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353981/0/en/unicycive-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","UNCY","BK4539","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660282383","title":"Unicycive Therapeutics price target raised to $15 from $13 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2660282383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660282383?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:40","pubTimestamp":1787229649,"startTime":"0","endTime":"0","summary":"Benchmark analyst Bruce Jackson raised the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $13 and keeps a Speculative Buy rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-raised-to-15-from-13-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-raised-to-15-from-13-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660811404","title":"U.S. Research Roundup-Amgen, Analog Devices, Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2660811404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660811404?lang=en_us&edition=fundamental","pubTime":"2026-08-20 15:47","pubTimestamp":1787212055,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amgen, Analog Devices, ModernaAug 20 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Analog D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL4N44H0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADI","CRWD","MSGE","MRNA","AIPI","WHD","SNOW","XLV","IBBQ","GKOS","FRNM","ARTY","ADSK","NRGV","XNTK","IHF","APA","HCA","PJP","CING","BILL","NIQ","WOLF","KIDS","AMGN","SMHX","MRK","RARE","SPHR","TGT","RLAY","LWAY","KBWP","WISE","LOW","IHE","TRUH","TJX","EL","LNSR","WDAY","PGR","PCTY","UNCY","ALIT","ABBV","ALL","EPR","MRVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660148835","title":"Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660148835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660148835?lang=en_us&edition=fundamental","pubTime":"2026-08-17 15:39","pubTimestamp":1786952395,"startTime":"0","endTime":"0","summary":"B. Riley lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $20 from $22 and keeps a Buy rating on the shares. The Q2 update was c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-20-from-22-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-20-from-22-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660007106","title":"Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Drug Pipeline, Led by OLC for Dialysis Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2660007106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660007106?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:58","pubTimestamp":1786931915,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemiaUnicycive outlined plans to resubmit its NDA for oxylanthanum carbonate, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbkxRdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314152","title":"Clene Q2 Net Loss Widens on Higher Other Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711241,"startTime":"0","endTime":"0","summary":"Clene Q2 net loss widens on higher other expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr, driven by higher other expensesCompany closed $7 mln stock offering and extended debt ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","UNCY","BK4139","CLNN","BK4539","AEON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACHV","PROK","UNCY","ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659316818","title":"Unicycive Therapeutics Price Target Cut to $20.00/Share from $22.00 by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2659316818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659316818?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:05","pubTimestamp":1786629900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659501581","title":"B. Riley Securities Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659501581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659501581?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:36","pubTimestamp":1786628208,"startTime":"0","endTime":"0","summary":"B. Riley Securities analyst Mayank Mamtani maintained a Buy rating on Unicycive Therapeutics today and set a price target of $20.00. According to T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-securities-reaffirms-their-buy-rating-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-securities-reaffirms-their-buy-rating-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154446","title":"B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154446","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154446?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:21","pubTimestamp":1786623702,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) has an average rating of buy and mean price target of $31.30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659180317","title":"Unicycive Therapeutics Inc : Guggenheim Cuts Target Price to $25 from $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2659180317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659180317?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:45","pubTimestamp":1786592752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN4491NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900699","title":"Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900699","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900699?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565676,"startTime":"0","endTime":"0","summary":"Inovio Q2 net loss narrows on warrant gain, lower costsOverviewUS biotech firm's Q2 net loss narrowed yr/yr, driven by non-cash warrant gainQ2 operating expenses fell due to lower compensation and dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N449116:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","BK4139","BK4539","TOVX","INO","BK4583","UNCY","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909429","title":"Unicycive Rises on Narrower Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909429?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:12","pubTimestamp":1786551150,"startTime":"0","endTime":"0","summary":"BUZZ-Unicycive rises on narrower quarterly loss** Shares of drug developer Unicycive TherapeuticsUNCY.Orise 9.2% to $5.46** Co posted Q2 net loss of $1.7 million, compared to a net loss of $6.5 millio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4491DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908540","title":"Unicycive Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908540","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908540?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:31","pubTimestamp":1786541509,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryUnicycive Therapeutics IncUNCY.OQreported a quarterly adjusted loss of 52 cents per share for the quarter end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974615","title":"Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974615","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:31","pubTimestamp":1786534264,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q2 net loss narrows on warrant liability changeOverviewUS kidney disease biotech's Q2 net loss narrowed from prior yearNet loss decline attributed to change in fair value of war","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHV","BK4007","UNCY","PROK","BK4539","SCYX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971054","title":"Unicycive Therapeutics Q2 EPS USD -0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971054?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:20","pubTimestamp":1786533640,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXSW5DRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971778","title":"Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971778?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:19","pubTimestamp":1786533580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA96DVLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658710919","title":"Unicycive Therapeutics - Q2 Net Loss was $1.70 Mln or $0.06 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658710919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658710919?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:19","pubTimestamp":1786533580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA96DVLX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":-0.0926},{"period":"1month","weight":-0.1398},{"period":"3month","weight":-0.2993},{"period":"6month","weight":-0.2868},{"period":"1year","weight":0.1736},{"period":"ytd","weight":-0.1681}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":-0.01515},{"month":2,"riseRate":0.5,"avgChangeRate":0.108299},{"month":3,"riseRate":0.5,"avgChangeRate":0.764023},{"month":4,"riseRate":0.5,"avgChangeRate":-0.067952},{"month":5,"riseRate":0.25,"avgChangeRate":-0.081225},{"month":6,"riseRate":0,"avgChangeRate":-0.255499},{"month":7,"riseRate":0.2,"avgChangeRate":-0.068802},{"month":8,"riseRate":0.2,"avgChangeRate":-0.125164},{"month":9,"riseRate":0.6,"avgChangeRate":0.028261},{"month":10,"riseRate":0.75,"avgChangeRate":0.058419},{"month":11,"riseRate":0.75,"avgChangeRate":0.140721},{"month":12,"riseRate":0.5,"avgChangeRate":0.132496}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}